Ibrutinib/ibrutinib drug description: manufacturer, drug properties and usage details

Ibrutinib (trade name: Yike, English name: Ibrutinib), also known as ibrutinib, is an innovative drug jointly developed and commercialized by the multinational pharmaceutical companies AbbVie and Johnson & Johnson. As the world's first irreversible inhibitor of Bruton's tyrosine kinase (BTK), ibrutinib has achieved remarkable results in the treatment of lymphoma.

1. Manufacturer

Ibrutinib is jointly developed and commercialized by AbbVie and Johnson & Johnson. The two companies have important positions in the global pharmaceutical market. With their strong R&D capabilities and extensive sales network, ibrutinib has quickly become an emerging drug in the global lymphoma treatment field.

2. Drug properties

The main mechanism of action of ibrutinib is to irreversibly inhibit the activity of BTK by selectively covalently binding to the cysteine residue (Cys-481) in the active site of BTK. BTK is a key component of the B lymphocyte antigen receptor (BCR) signaling pathway and is involved in the development, maturation, proliferation and apoptosis of B lymphocytes. Ibrutinib effectively controls the growth and spread of lymphoma cells by blocking this signaling pathway.

3. How to use

Ibrutinib capsule is an oral anti-tumor drug. The usage and dosage must be strictly followed by the doctor's instructions. It is generally recommended to take it once a day with food, and the medication time should be roughly fixed. For patients with MZL and MCL, the recommended dose is 560mg (i.e. 4 capsules of 140mg); while for patients with CLL, SLL and WM, the recommended dose is 420mg.

While taking ibrutinib, patients should avoid taking it with grapefruit juice, coffee, or orange juice to avoid affecting drug absorption. If adverse reactions occur, the doctor should be informed immediately and the treatment plan should be adjusted under his guidance. In patients with hepatic impairment, especially those with moderate or severe hepatic impairment, ibrutinib should be avoided or adjusted to the lowest recommended dose.

In summary, ibrutinib, as an innovativeBTK inhibitor, provides a new treatment option for lymphoma patients. Its unique mechanism of action and good safety profile enable ibrutinib to achieve significant efficacy in clinical application. However, patients still need to strictly follow medical instructions and pay attention to drug interactions and adverse reactions when using ibrutinib to ensure the safety and effectiveness of the treatment. Currently, there are many versions of ibrutinib on sale, with different prices. Patients should choose according to their needs.